Thursday, May 22, 2014
the only marketed drug for idiopathic pulmonary fibrosis, has shown a mortality
benefit, the effects are modest and there remains room for improvement. New
preclinical findings suggest that inhibiting NADPH
oxidase 4 could both resolve and reverse fibrosis.1
Scott Turner, EVP of R&D at KineMed Inc., wanted to see more
evidence that Nox4 inhibition helps to actively resolve fibrosis in aged mice.
Boettner, B. SciBX 7(20);
doi:10.1038/scibx.2014.573 Published online May 22, 2014
1. Hecker, L. et al. Sci. Transl. Med.; published
online April 9, 2014; doi:10.1126/scitranslmed.3008182 Contact:
Victor J. Thannickal, The University of Alabama at Birmingham, Birmingham, Ala.
Contact: Louise Hecker, same affiliation as above e-mail:
2. Hinz, B.
et al. Am. J. Pathol. 170, 1807-1816
3. Hecker, L. et al. Nat. Med. 15,
AND INSTITUTIONS MENTIONED
Albany Medical College, Albany, N.Y.
Boehringer Ingelheim GmbH, Ingelheim, Germany
Genkyotex S.A., Plan-les-Ouates,
Institut National de la Santé et de la Recherche Médicale, Paris, France
(NASDAQ:ITMN), Brisbane, Calif.
National Institutes of Health, Bethesda, Md.
Paris Diderot University, Paris, France
The University of Alabama at Birmingham, Birmingham, Ala.
The University of Arizona, Tucson, Ariz.
The University of Texas Health Science Center at San
Antonio, San Antonio, Texas